Message from the Dean
Greetings from the Dean of the School of Medicine/Graduate School of Medicine
On behalf of the Nagoya University School of Medicine and Graduate School of Medicine, I am honored to have this opportunity to say a few words of greeting.
agoya University is one of the oldest universities in Japan, with 140 years of history and tradition since its founding as a temporary medical school and hospital for the Nagoya Domain in 1871 (Year 4 of the Meiji Period). In 1939, Nagoya University became Japan’s 7th Imperial University, consisting of a faculty of medicine and a faculty of science and engineering, and in 1949, after the Second World War, it made a new start as Nagoya University under the new education system.
In 1997, the Department of Health Sciences was established in 1997, bringing 2 faculties ‒ Medicine and Health Sciences ‒ under the umbrella of the School of Medicine. In 2000, a reorganization stressing the strengthening of the graduate school was completed. The Graduate School of Medicine was reorganized into 4 major programs combining basic medicine and clinical medicine: Integrated Molecular Medicine, Cell Information Medicine, Function Construction Medicine, and Health & Community Medicine. Then, in 2013, these 4 programs were merged into the Program in Integrated Medicine, with 3 divisions: Basic Medicine, Clinical Medicine, and Clinical Pharmacology. In the Division of Clinical Pharmacology, new laboratories were established in the fields of Biostatistics and Toxicogenomics to promote drug discovery and translational research. New courses were also offered through a collaboration with Meijo University Graduate School of Pharmacy, an industry-university collaboration with Astellas Pharma Inc. and other pharmaceutical companies, and one with the Institute of Statistical Mathematics and Pharmaceutical and Medical Devices Agency, aiming to nurture human resources with the capacity to be active in the drug discovery field and promote clinical trials, an area in which Japan is considered to be lag behind. Concurrent with this reorganization of the Graduate School of Medicine, Medical Science Research Building 3 was completed in July of 2014, representing a great leap forward in terms of the foundation for research and graduate school education.
In the past 4 years, global collaboration at the graduate school level has been cited as a challenge that the graduate school needs to devote special efforts to. About 10 researchers were sent to each of the Medical University of Vienna (January of 2013) and the University of Adelaide in Australia (May of 2013) to engage in symposia. Visits were made to the University of Freiburg in Germany and the University of Strasbourg in France in November of the same year to discuss cooperation. As a result, the president, vice-president, and deans of the schools of medicine of the University of Adelaide and the University of Freiburg assembled together at our Graduate School of Medicine to conclude a cooperative agreement to promote exchange at the graduate school level in March of 2014. In October 2015, Nagoya University Graduate School of Medicine launched Japan’s first joint degree program with an International University, the University of Adelaide.
In the future we will renew our efforts to develop the Graduate School of Medicine into program with a real global presence that can devote even more attention to the nurturing of young and mid-level human resources and can disseminate many outstanding basic researches and clinical researches to the world. We ask you all to lend us your strong support.
Masahide TAKAHASHI, M. D., Ph. D.
Dean of the School of Medicine and Graduate School of Medicine
Fields of Specialization
1. Experimental Pathology
2. Tumor Biology
3. Molecular Neurobiology
１． Studies on biological properties of cancer cells
２． Molecular mechanisms of cancer invasion and metastasis
３． Development of the nervous system and the molecular pathogenesis of neuropsychiatric disorders
１． Yamamura, Y., Asai, N., Enomoto, A., Kato, T., Mii, S., Kondo, Y., Ushida, K.,
Niimi, K., Tsunoda, N., Nagino, M., Ichihara, S., Furukawa, K., Maeda, K.,
Murohara, T. and Takahashi. M.
Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor
progression. Cancer Res. 75: 813-823 (2015)
２． Weng, L., Enomoto, A., Miyoshi, H., Takahashi, K., Asai, N., Morone, N., Jiang, P.,
An, J., Kato, T., Kuroda, K., Watanabe, T., Asai, M., Ishida-Takagishi, M.,
Murakumo, Y., Nakashima, H., Kaibuchi, K. and Takahashi, M.
Regulation of cargo-selective endocytosis by dynamin 2 GTPase-activating
protein girdin. EMBO J. 33: 2098-2112 (2014).
３． Kato, T., Enomoto, A., Watanabe, T., Haga, H., Ishida, S., Kondo, Y., Furukawa,
K., Urano, T., Mii, S., Weng, L., Takagishi, M., Asai, M., Asai, N., Kaibuchi, K.,
Murakumo, Y. and Takahashi, M.
TRIM27/MTRF-B-dependent integrin beta1 expression defines leading cells in
cancer cell collecitives. Cell Rep. 7: 1156–1167 (2014)
４． Ishida-Takagishi, M., Enomoto, A., Asai, N., Ushida, K., Watanabe, T., Hashimoto, T.,
Kato, T., Weng, L., Matsumoto, S., Asai, M., Murakumo, y., Kaibuchi, K., Kikuchi, A.
and Takahashi, M.
The Dishevelled-associating protein Daple controls the non-canonical Wnt/Rac
pathway and cell motility. Nature Commun. 3: 859 (2012).
５． Enomoto, A., Asai, N., Namba, T., Wang, Y., Kato, T., Tanaka, M., Tatsumi, H.,
Taya, S., Tsuboi, D., Kuroda, K., Kaneko, N., Sawamoto, K., Miyamoto, R.,
Jijiwa, M., Murakumo, Y., Sokabe, M., Seki, T., Kaibuchi, K. and Takahashi, M.
Roles of Disrupted-in-Schizophrenia 1-interacting protein Girdin in postnatal
development of the dentate gyrus. Neuron 63: 774-787 (2009).
６． Kitamura, T., Asai, N., Enomoto, A., Maeda, K., Kato, T., Ishida, M., Jiang, P.,
Watanabe, T., Usukura, J., Kondo, T., Costantini, F., Murohara, T. and
Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin.
Nature Cell Biol. 10:329-337 (2008).
７． Enomoto, A., Murakami, H., Asai, N., Morone, N., Watanabe, T., Kawai, K.,
Murakumo, Y., Usukura, J., Kaibuchi, K., and Takahashi, M.
Akt/PKB regulates actin organization and cell motility via Girdin/APE.
Dev. Cell 9: 389-402 (2005).
８． Klein, R.D., Sherman, D., Ho, W.-H., Stone, D., Bennett, G. L., Moffat, B.,
Vandlen, R., Simmons, L., Gu, Q., Hongo, J.-A., Devaux, B., Poulsen, K.,
Armanini, M., Nozaki, C., Asai, N., Goddard, A., Phillips, H., Henderson, C. E.,
Takahashi, M. and Rosenthal, A.
A GPI-linked protein that interacts with Ret to form a candidate neurturin
receptor. Nature 387: 717-721 (1997).
９． Treanor, J.J.S., Goodman, L., de Sauvage, F., Stone, D.M., Poulsen, K.T., Beck,
C.D., Gray, C., Armanini, M.P., Pollock, R.A., Hefti, F., Phillips, H.S., Goddard, A.,
Moore, M.W., Buj-Bello, A., Davies, A., Asai, N., Takahashi, M., Vandlen, R.,
Henderson, C.E. and Rosenthal, A.
Characterization of a multicomponent receptor for GDNF. Nature 382: 80-83 (1996).
10．Asai, N., Iwashita, T., Matsuyama, M. and Takahashi, M.
Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia
2A mutations. Mol. Cell. Biol. 15: 1613-1619 (1995).
11．Takahashi, M., Ritz, J. and Cooper, G.M.
Activation of a novel human transforming gene, ret, by DNA rearrangement.
Cell 42: 581-588 (1985).